Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bachas

Showing results (151-160 of 433) with videos related to

Pageof 44
Sort By:
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
The European Physical Journal. C, Particles and Fields|August 14, 2015
Search for the Standard Model Higgs boson produced in association with top quarks and decaying into [Formula: see text] in [Formula: see text] collisions at [Formula: see text] with the ATLAS detectorG Aad, B Abbott, J Abdallah, et al.
Physical Review Letters|September 16, 2015
Measurements of the Total and Differential Higgs Boson Production Cross Sections Combining the H→γγ and H→ZZ^{*}→4ℓ Decay Channels at sqrt[s]=8  TeV with the ATLAS DetectorG Aad, B Abbott, J Abdallah, et al.
Pageof 44

Showing results (151-160 of 433) with videos related to

Sort By:
Pageof 44
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Blood|November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Blood|December 15, 2025
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Peter J M Valk, Christian Thiede, et al.
The European Physical Journal. C, Particles and Fields|August 14, 2015
Search for the Standard Model Higgs boson produced in association with top quarks and decaying into [Formula: see text] in [Formula: see text] collisions at [Formula: see text] with the ATLAS detectorG Aad, B Abbott, J Abdallah, et al.
Physical Review Letters|September 16, 2015
Measurements of the Total and Differential Higgs Boson Production Cross Sections Combining the H→γγ and H→ZZ^{*}→4ℓ Decay Channels at sqrt[s]=8  TeV with the ATLAS DetectorG Aad, B Abbott, J Abdallah, et al.
Pageof 44